Science Strategic Acquisition Corp. Alpha Class A Common Stock
SSAA
SSAA was delisted on the 12th of December, 2022.
0 hedge funds and large institutions have $0 invested in Science Strategic Acquisition Corp. Alpha Class A Common Stock in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 86 closing their positions.
100% less funds holding
Funds holding: 87 → 0 (-87)
100% less capital invested
Capital invested by funds: $270M → $0 (-$270M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 86
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Saba Capital Management
New York
|
-$23.6M |
| 2 |
GCL
Glazer Capital LLC
New York
|
-$18.4M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$14.6M |
| 4 |
SC
Sculptor Capital
New York
|
-$12.9M |
| 5 |
GL
Governors Lane
New York
|
-$9.66M |
SSAA Hedge Fund Activity: Q4 2022 in Review
0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Science Strategic Acquisition Corp. Alpha Class A Common Stock (SSAA) for Q4 2022, worth a combined $0 — down 100% from $270M a quarter earlier.
Sellers outnumbered buyers: 86 funds closed out of SSAA and 0 opened new positions — a net loss of 86 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Saba Capital Management, exiting entirely with an estimated $23.6M sold.
- 0 institutional investors held Science Strategic Acquisition Corp. Alpha Class A Common Stock (SSAA) as of Q4 2022, down from 87 in Q3 2022.
- Funds reported $0 of Science Strategic Acquisition Corp. Alpha Class A Common Stock stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new Science Strategic Acquisition Corp. Alpha Class A Common Stock positions in Q4 2022 and 86 closed out, a net change of -86 holders.
- The largest Science Strategic Acquisition Corp. Alpha Class A Common Stock seller in Q4 2022 was Saba Capital Management, an estimated $23.6M sold.
Based on aggregated 13F filings for Q4 2022.